AUS
NZ
UK
CA
USA
IND
Uniphar plc (-UPR), the Dublin-based global healthcare services company, reported an adjusted earnings per share increase of roughly 11% for the first half of 2026, supported by approximately 7% organic gross profit growth across its diverse portfolio. The company announced a revised launch date for its advanced distribution centre in Ireland, now expected to become operational in February 2027 instead of earlier in the year, with an estimated 0m additional capital expenditure. This update indicates Uniphar remains on course to achieve its full-year divisional targets and sustain progress toward its 00m EBITDA objective by 2028.
Key Points
- Uniphar plc (-UPR) is an international diversified healthcare services firm headquartered in Dublin, serving over 200 multinational pharmaceutical and medical technology manufacturers across Europe, North America, APAC, and MENA.
- The company recorded about 11% adjusted EPS growth in H1 2026, driven by around 7% organic gross profit expansion across the Group.
- The new high-tech distribution centre in Ireland is now scheduled to launch in February 2027 with a phased rollout during H1 2027, requiring roughly 0m incremental capital expenditure but positively impacting FY 2026 adjusted EPS due to deferred depreciation and amortisation.
- Uniphar Pharma is on track for double-digit organic gross profit growth for the full year; Uniphar Medtech anticipates high single-digit growth; and Uniphar Supply Chain & Retail expects mid-single-digit growth.
- Investors should watch for the interim results release on 8 September 2026 and monitor progress toward the 00m EBITDA target by 2028, with at least 80% expected from organic growth.
Uniphar’s Diversified Healthcare Model Spanning Pharma, Medtech, and Supply Chain Divisions
Uniphar plc operates as a global diversified healthcare services company segmented into three core divisions: Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail. Headquartered in Dublin, Ireland, it supports over 200 multinational pharmaceutical and medical technology manufacturers across Europe, North America, Asia-Pacific, and the Middle East and North Africa, delivering to more than 160 countries worldwide. This extensive geographic reach and varied client base provide resilience and multiple avenues for growth.
Each division pursues distinct strategic goals aligned with its market positioning. Uniphar Pharma offers comprehensive services throughout the pharmaceutical product lifecycle, assisting pharma and biotech firms in launching innovative medicines globally. Uniphar Medtech serves as a leading Pan-European medical device distributor and solutions partner, focusing on expanding services and market reach across Europe. Uniphar Supply Chain & Retail is Ireland’s foremost pharmaceutical wholesaler with a growing retail pharmacy symbol group. The company’s overarching mission is to enhance patient access to pharmaco-medical products by strengthening connections between manufacturers and healthcare stakeholders, establishing Uniphar as a vital infrastructure provider in the global healthcare supply chain.
Robust Organic Growth Drives 11% Adjusted EPS Rise in H1 2026
Uniphar plc achieved approximately 11% adjusted earnings per share growth in the first half of 2026, aligned with Group expectations, supported by roughly 7% organic gross profit growth across operations. This performance reflects steady trading momentum and effective execution of the growth strategy during the six months ending 30 June 2026. The company highlighted that this growth was achieved without significant external factors, indicating strong underlying operational performance. The Group maintained focus on organic expansion and disciplined capital deployment throughout the period.
The update notes that Uniphar’s diversified portfolio contributed to the growth trajectory. Full-year trading expectations remain unchanged after the strong first half, demonstrating management’s confidence in sustaining growth. The net bank debt to EBITDA ratio was 2.4x at June 2026, reflecting the expected reversal of previously noted favourable working capital movements. This leverage remains within acceptable limits, underscoring the company’s ability to service debt while investing in growth. The balance of strong liquidity and profitable expansion indicates prudent financial management alongside operational strength.
Uniphar Pharma Poised for Double-Digit Organic Gross Profit Growth in 2026
Uniphar Pharma, the Group’s global pharmaceutical services division, recorded high single-digit organic gross profit growth in H1 2026 and is positioned to achieve double-digit organic gross profit growth for the full year. Operating across the pharmaceutical product lifecycle, it provides specialist support enabling pharma and biotech companies to bring innovative medicines to market. The strong first-half momentum and management’s confidence suggest accelerating growth or realisation of previously delayed projects in H2 2026.
The division’s strategy aims to build a leading platform improving access to specialist medicines beyond traditional distribution channels. This value-added approach offers higher-margin services compared to commodity wholesale distribution. The H1 2026 results provide a solid foundation for full-year double-digit growth, reflecting successful service development and market penetration. The pharmaceutical services sector is presenting growth opportunities that Uniphar Pharma is effectively capitalising on.
Medtech Division Sustains High Single-Digit Growth Outlook for 2026
Uniphar Medtech, the Group’s Pan-European medical device distributor and solutions provider, achieved high single-digit organic gross profit growth in H1 2026 and remains on track for similar full-year growth. The division focuses on expanding service offerings and entering new specialties and customer segments across Europe. The consistent performance suggests a stable growth trajectory within the medtech sector, which differs from pharmaceutical distribution dynamics.
The division’s strategy prioritises growing addressable markets by serving new medical specialties and onboarding new manufacturers. Maintaining high single-digit organic growth throughout 2026 indicates effective market expansion without operational disruptions or cyclical challenges. No material headwinds were reported, suggesting a stable market environment. Investors may view this division as a reliable contributor to profitability and cash flow, aligned with European healthcare spending and adoption of new medical technologies.
Supply Chain & Retail Division Forecasts Mid-Single-Digit Growth for 2026
Uniphar Supply Chain & Retail, Ireland’s leading pharmaceutical wholesaler with an expanding retail pharmacy symbol group, posted mid-single-digit organic gross profit growth in H1 2026 and expects similar growth for the full year. This mature segment holds a dominant position in Irish pharmaceutical wholesaling and a growing portfolio of own-brand, in-licensed, and consumer healthcare products. The consistent mid-single-digit guidance reflects the predictable nature of wholesale pharmacy distribution influenced by prescription volumes, pricing, and retail expansion.
The division focuses on increasing wholesale market share, expanding the retail pharmacy network, and developing proprietary and in-licensed consumer products. Mid-single-digit organic growth indicates sustainable, profitable expansion without heavy capital or operational changes. This division remains a cash-generative base funding investments in higher-growth areas like Uniphar Pharma while delivering shareholder value. The upcoming high-tech distribution facility in Ireland will enhance efficiency and competitiveness once operational in H1 2027.
Irish Distribution Hub Launch Delayed to February 2027 with 0 Million Additional Capex
Uniphar announced the new high-tech distribution facility in Ireland will now become operational in February 2027, with a phased rollout through H1 2027, delayed from earlier in the year. The extended timeline allows for thorough end-to-end testing and reduces execution risk during the Group’s peak trading season in Q4. The project requires about 0m additional capital expenditure beyond prior guidance, representing a significant update to capital plans. Management views the delay as a measure to ensure operational stability during a critical period for Irish pharmaceutical distribution.
The postponement defers depreciation and amortisation charges, benefiting FY 2026 adjusted EPS expectations by shifting non-cash expenses into 2027 and beyond. The 0m incremental capex may reflect cost underestimation or scope expansion, while the phased launch prioritises operational reliability over speed. Once active, the facility will boost distribution capacity and efficiency for the Supply Chain & Retail division, supporting long-term margin enhancement and growth in Ireland.
Liquidity Remains Strong with 2.4x Net Bank Debt to EBITDA Ratio
Uniphar maintains a robust liquidity profile, with a net bank debt to EBITDA ratio of 2.4x as of June 2026. This ratio reflects the anticipated reversal of prior favourable working capital effects, indicating the company benefited from optimisation in H1 but expects normalisation in H2. The leverage remains within typical covenant limits for diversified healthcare services firms and supports investment capacity for growth initiatives, including the 0m distribution facility capex and potential acquisitions.
Strong liquidity despite increased capital spending and ongoing M&A efforts demonstrates disciplined financial management and confidence in cash generation. Management emphasises M&A as a key growth component, maintaining a disciplined capital allocation approach while actively evaluating acquisition opportunities. No specific deals were disclosed. Investors may see current leverage as balancing financial flexibility with prudent gearing, preserving optionality for value-accretive acquisitions.
Management Confirms 00 Million EBITDA Target by 2028 with 80% Organic Growth
Group CEO Ger Rabbette reaffirmed confidence in reaching the 00m EBITDA target by 2028, with a minimum of 80% growth expected organically. This target underscores commitment to profitable internal growth while allowing a minority contribution from acquisitions. Achieving 00m EBITDA marks a significant milestone, implying sustained strong organic growth across all divisions beyond 2026.
Rabbette stated, "Uniphar has delivered a strong first half, with continued organic gross profit growth across the Group," and "trading remains robust and the business is progressing as expected." This commentary supports the quantitative results in the trading update. The company anticipates maintaining momentum in H2 and meeting divisional growth goals for the full year. The emphasis on 80% organic growth highlights a focus on building durable internal capabilities over reliance on external acquisitions.
Interim Results Scheduled for September 2026 with Investor Call
Uniphar plans to release interim results for the six months ended 30 June 2026 at 07:00 am (BST) on 8 September 2026. A conference call for analysts and investors will follow at 09:00 am (BST) the same day to discuss the results. The interim results and presentation will be available on the company website at www.uniphar.ie upon publication. This approach offers investors detailed financial insights and direct engagement with management on H1 performance and outlook.
The timing provides comprehensive financial data and management commentary about five weeks after this trading update. The conference call enables real-time dialogue and detailed questions on divisional results, capital expenditure for the distribution facility, and acquisition pipeline progress. Investors should review the September 8 release for detailed EBITDA, cash flow, and any updates impacting 2026 guidance and medium-term strategy. The presentation will clarify H1 performance drivers and management’s confidence in full-year targets.
This article is for informational purposes only and does not constitute investment advice. All facts and figures are sourced from the Uniphar plc announcement dated 28 July 2026. Investors should perform their own due diligence and seek independent financial, legal, and tax advice before making investment decisions related to Uniphar plc or its securities. Past performance and management guidance do not guarantee future results. Share prices and valuations are subject to market risks and volatility. Investing in listed securities involves risk, including potential capital loss.
